No Data
Hong Kong stock market review: Hang Seng Index fell by 0.53%, Hang Seng Tech Index fell by 1.24%, mainland real estate stocks showed a noticeable decline.
Most of the large technology stocks fell, with Kuaishou dropping 11.7% after earnings, marking the weakest performance.
The opening ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute.
The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute", established by the special zone government and fully owned, officially opened today (21st) at the Hong Kong Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center" in Shenzhen Park also opened on the same day. The "one institute and one center" has become the first benchmark for the coordinated development of the "one zone and two parks" in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Secretary for Administration and Home Affairs, Cheuk Wing-hing, stated that the National "14th Five-Year Plan" clearly supports Hong Kong in building an international innovation and technology center. The "Development Plan for Shenzhen Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone" also strongly supports the coordinated development of science and te
Behind the Hong Kong stock CXO's sideways oscillation, foreign investors continue to sell while domestic investors accelerate their entrance.
Recently, the public fund medical hold positions data for Q3 2024 has been gradually disclosed, with a noticeable increase in CXO positions. Additionally, the Hong Kong Stock Connect funds have significantly bought CXO symbol stocks in the past 60 days, reflecting the current optimistic attitude of domestic funds towards the subsequent rebound of the CXO sector.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Hong Kong stocks abnormal fluctuations | CRO concept stocks lead the gains, institutions believe that the future performance recovery is worth looking forward to. The listing of innovative drugs in the United States has demands for reducing research and d
CRO concept stocks lead the gains. As of the press release, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.
No Data
No Data